

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Doses First Patient in DENALI Part 2 Trial for PROC with Azenosertib
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for patients with Cyclin E1+ platinum-resistant ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azenosertib Shows Activity in Platinum-Resistant Ovarian Cancer
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for patients with Cyclin E1+ platinum-resistant ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Announces Fast Track Designation for Azenosertib and Upcoming Data Event
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Pharmaceuticals Reports FDA Lifts Partial Clinical Hold on Azenosertib Studies
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 16, 2024
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2024
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Filipa Lynce
Deal Size : Inapplicable
Deal Type : Inapplicable
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
Details : Azenosertib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2024
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Filipa Lynce
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Brandon Huffman
Deal Size : Inapplicable
Deal Type : Inapplicable
ZN-c3 + Gemcitabine in Pancreatic Cancer
Details : Zentalis (Azenosertib) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Zentalis
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2023
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Brandon Huffman
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZN-c3 (azenosertib) is a potentially first-in-class and best-in-class small molecule WEE1 inhibitor in development for the treatment of ovarian cancer and uterine serous carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Azenosertib,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
Details : ZN-C3 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : Azenosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azenosertib,Cetuximab,Encorafenib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer
Details : Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Azenosertib,Cetuximab,Encorafenib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
